October 21, 2022

Patients respond to cBHT “Special Report”

This week APC emailed a special report to thousands of patients and prescribers of compounded hormones to inform them about FDA’s prohibition of Thyroid USP for use in compounding, and to update them on the threat to compounded hormone therapy generally.

In addition to all APC members, state pharmacy associations, and other interested individuals, the email was sent to: 

  • More than 5,000 patients and prescribers who had visited compounding.com in the past year.
  • More than 60,000 consumers who are part of APC’s Patients for Personalized Prescriptions (P3) group.
  • Nearly 2,000 prescribers who recently signed a joint letter to FDA Commissioner Robert Califf about FDA’s threat to restrict cBHT.

Thus far, the email campaign has resulted in 19 additional contributions—totaling more than $16,000—to APC’s Save Compounded Hormones Campaign. It has also resulted in more than 70 new patient testimonials this week at compounding.com.

As you may know, our ability to continue to engage patients, prescribers, and policymakers on this issue is in jeopardy. Please help us continue to fight for your ability to treat patients with compounded hormone therapy. Give to the campaign via the button below.